2CL Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - BridgeBio Pharma Inc

Watchlist Manager

Watchlist

Price: 0.057 EUR Market Closed

Market Cap: €8.4m

B	BridgeBio Pharma Inc XBER:2CL	US
	Aurinia Pharmaceuticals Inc NASDAQ:AUPH	CA
	LG Display Co Ltd KRX:034220	KR
W	Worldline SA F:WO6	FR

Profitability Summary

BridgeBio Pharma Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

95%

Strong 3Y Average Gross Margin

89%

Declining Gross Margin

96% > 95%

Negative Operating Margin

-87%

Negative 3Y Average Operating Margin

-1 944%

Operating Margin is Increasing

-566% > -87%

Negative Net Margin

-124%

Negative 3Y Average Net Margin

-2 145%

Net Margin is Increasing

-546% > -124%

Negative Free Cash Flow Margin

-78%

Negative 3Y Average Free Cash Flow Margin

-1 791%

Free Cash Flow Margin is Increasing

-525% > -78%

Exceptional ROE

37%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-277%

ROIC is Increasing

-336% > -141%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.